252 related articles for article (PubMed ID: 17064405)
21. The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning.
Vaughan HA; St Clair F; Scanlan MJ; Chen YT; Maraskovsky E; Sizeland A; Old LJ; Cebon J
Cancer Immun; 2004 Jul; 4():5. PubMed ID: 15255672
[TBL] [Abstract][Full Text] [Related]
22. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival.
Kurtenkov O; Klaamas K; Mensdorff-Pouilly S; Miljukhina L; Shljapnikova L; Chuzmarov V
Acta Oncol; 2007; 46(3):316-23. PubMed ID: 17450466
[TBL] [Abstract][Full Text] [Related]
23. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC)--potential implications for clinical management and treatment decisions.
Hass HG; Schmidt A; Nehls O; Kaiser S
Oral Oncol; 2008 Jan; 44(1):78-85. PubMed ID: 17350326
[TBL] [Abstract][Full Text] [Related]
24. Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.
Croce MV; Rabassa ME; Pereyra A; Segal-Eiras A
Pathol Oncol Res; 2005; 11(2):74-81. PubMed ID: 15999150
[TBL] [Abstract][Full Text] [Related]
25. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
[TBL] [Abstract][Full Text] [Related]
26. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
[TBL] [Abstract][Full Text] [Related]
27. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women.
Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T
Breast Cancer Res Treat; 2005 Aug; 92(3):223-30. PubMed ID: 16155793
[TBL] [Abstract][Full Text] [Related]
28. Expression of MUC1 mucins in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder.
Kawamoto T; Shoda J; Irimura T; Miyahara N; Furukawa M; Ueda T; Asano T; Kano M; Koike N; Fukao K; Tanaka N; Todoroki T
Clin Cancer Res; 2001 May; 7(5):1333-42. PubMed ID: 11350903
[TBL] [Abstract][Full Text] [Related]
29. Detection of circulating mammary mucin (Muc1) and MUC1 immune complexes (Muc1-CIC) in healthy women.
Croce MV; Isla-Larrain MT; Price MR; Segal-Eiras A
Int J Biol Markers; 2001; 16(2):112-20. PubMed ID: 11471893
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in mucin immunohistochemistry in salivary gland tumors and head and neck squamous cell carcinoma.
Mahomed F
Oral Oncol; 2011 Sep; 47(9):797-803. PubMed ID: 21723776
[TBL] [Abstract][Full Text] [Related]
31. Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas.
Wang JY; Chang CT; Hsieh JS; Lee LW; Huang TJ; Chai CY; Lin SR
J Surg Oncol; 2003 Aug; 83(4):253-60. PubMed ID: 12884239
[TBL] [Abstract][Full Text] [Related]
32. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy.
Cloosen S; Arnold J; Thio M; Bos GM; Kyewski B; Germeraad WT
Cancer Res; 2007 Apr; 67(8):3919-26. PubMed ID: 17440107
[TBL] [Abstract][Full Text] [Related]
33. Correlation between anti-survivin antibody and survivin mRNA expression in head and neck cancer patients.
Uemura N; Kodama S; Nomi N; Okamoto T; Suzuki M
Acta Otolaryngol; 2010 Aug; 130(8):959-65. PubMed ID: 20100132
[TBL] [Abstract][Full Text] [Related]
34. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer.
Tang Y; Cui X; Xiao H; Qi S; Hu X; Yu Q; Shi G; Zhang X; Gu J; Yu Y; Wang L; Li Y
Mol Med Rep; 2017 May; 15(5):2659-2664. PubMed ID: 28447743
[TBL] [Abstract][Full Text] [Related]
35. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma.
Katayama A; Ogino T; Bandoh N; Nonaka S; Harabuchi Y
Clin Cancer Res; 2005 Apr; 11(8):2937-46. PubMed ID: 15837745
[TBL] [Abstract][Full Text] [Related]
36. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer.
Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K
J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
38. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.
Lavieille JP; Lubin R; Soussi T; Reyt E; Brambilla C; Riva C
Anticancer Res; 1996; 16(4C):2385-8. PubMed ID: 8816839
[TBL] [Abstract][Full Text] [Related]
39. Circulating IgG response to stromelysin-3, collagenase-3, galectin-3 and mesothelin in patients with pharynx/larynx squamous cell carcinoma.
Suarez-Alvarez B; Garcia Suarez MM; Argüelles ME; Sampedro A; Alvarez Marcos C; Mira E; Van den Brul FA; Liu FT; Chowdhury PS; de los Toyos JR
Anticancer Res; 2001; 21(5):3677-84. PubMed ID: 11848542
[TBL] [Abstract][Full Text] [Related]
40. Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma.
Inata J; Hattori N; Yokoyama A; Ohshimo S; Doi M; Ishikawa N; Hamada H; Kohno N
Int J Cancer; 2007 Jun; 120(12):2643-9. PubMed ID: 17294451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
